Múkósín (Acetylcysteine)

Acetylcysteine, the active ingredient in Múkósín, is a mucolytic agent presented as an oral formulation for oral use. It reduces mucus viscosity and is employed in the management of chronic respiratory conditions such as chronic bronchitis, COPD and cystic fibrosis.

GNH USA supplies Múkósín as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide, with established quality‑assurance processes and regulatory compliance across EU and other markets. The company provides batch‑tested product with full documentation to meet the needs of procurement teams and clinical pharmacists.

Múkósín (acetylcysteine) is used as a respiratory mucolytic to facilitate mucus clearance in several chronic and acute lung conditions, improving airway patency and patient comfort. - Chronic bronchitis: reduces mucus viscosity, aiding expectoration and relieving airway obstruction. - Chronic obstructive pulmonary disease (COPD): improves sputum clearance, which may lessen exacerbation frequency. - Cystic fibrosis: assists in thinning thick pulmonary secretions, supporting airway hygiene and respiratory function. - Bronchiectasis: facilitates mucus clearance, reducing infection risk. - Upper respiratory tract infections with productive cough: helps loosen mucus, improving symptom relief.

Acetylcysteine is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Nausea: mild to moderate feeling of stomach upset. - Vomiting: occasional emesis, usually transient. - Diarrhea: loose stools that resolve after discontinuation. - Abdominal discomfort: cramping or pain in the stomach area. - Rash: skin redness or mild itching. - Metallic taste: transient alteration of taste perception.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction with airway swelling and hypotension. - Severe bronchospasm: sudden narrowing of airways causing breathing difficulty. - Stevens‑Johnson syndrome: rare skin disorder with blistering and mucosal involvement.

When prescribing acetylcysteine, clinicians should consider several safety aspects. - Renal impairment: use with caution and monitor renal function. - Asthma: observe for possible bronchospasm after administration. - Pregnancy: prescribe only if the potential benefit outweighs the risk. - Drug interactions: review all concomitant medications for possible interactions. - Allergy: avoid in patients with known hypersensitivity to acetylcysteine. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Acetylcysteine may interact with other medicines; awareness of the interaction level helps guide monitoring.

Major Interactions (Avoid): - Nitroglycerin: concurrent use can cause severe hypotension. - Anticoagulants (e.g., warfarin): may increase bleeding risk. - Certain chemotherapy agents: potential for enhanced toxicity.

Moderate Interactions (Monitor Closely): - Macrolide antibiotics: may augment mucolytic effect. - Bronchodilators: monitor respiratory response. - Other mucolytics: additive effect may increase gastrointestinal irritation.